31.01.2024 Epigenomics AG  DE000A37FT41

EQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board


 

EQS-News: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board

31.01.2024 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board

Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory Board has appointed Mr. Hansjörg Plaggemars to the Executive Board effective February 1, 2024.

Hansjörg Plaggemars (53) has more than 20 years of management experience in finance in various European companies.

He started his career at KPMG Corporate Finance and has worked as a CFO for over 14 years in various industries, including software, retail, prefabricated housing and e-commerce. In 2014, Mr. Plaggemars joined Deutsche Balaton AG and founded his own consulting firm, Value Consult, in 2017. In this role, he supports various projects, mainly with a capital market orientation, in different functions and industries.

Hansjörg Plaggemars holds a degree in business administration from the University of Bamberg.

Dr. Helge Lubenow, Chairwoman of the Supervisory Board: „We are very pleased that Mr. Plaggemars with his extensive management experience and expertise in finance is joining Epigenomics AG.“

„I am looking forward to becoming part of the Epigenomics team,“ said Hansjörg Plaggemars.

 

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: [email protected]

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: [email protected]


Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

 



31.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: [email protected]
Internet: www.epigenomics.com
ISIN: DE000A37FT41
WKN: A37FT4
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1827313

 
End of News EQS News Service

1827313  31.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1827313&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1,15 1,53 1,13 0,84 6,20 0,49 0,34
EBITDA1,2 -9,95 -12,78 -14,16 -11,09 -1,94 -11,30 -2,91
EBITDA-Marge3 -865,22 -835,29 -1.253,10 -1.320,24 -31,29 -2.306,12
EBIT1,4 -10,29 -12,90 -14,67 -11,63 -2,35 -12,05 -4,50
EBIT-Marge5 -894,78 -843,14 -1.298,23 -1.384,52 -37,90 -2.459,18 -1.323,53
Jahresüberschuss1 -10,24 -12,69 -17,02 -11,69 -2,43 -12,02 -4,46
Netto-Marge6 -890,43 -829,41 -1.506,19 -1.391,67 -39,19 -2.453,06 -1.311,77
Cashflow1,7 -9,58 -10,35 -13,51 -9,57 -4,15 -12,02 -5,71
Ergebnis je Aktie8 -70,40 -75,20 -73,00 -40,40 -4,40 -14,80 -5,15
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Epigenomics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A37FT4 1,695 1,48
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -0,03
KBV KCV KUV EV/EBITDA
-0,19 - 4,38 -3,87
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 29.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2024 14.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,45% 169,05% -10,32% -68,13%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Epigenomics AG  ISIN: DE000A37FT41 können Sie bei EQS abrufen


Biotechnologie , A37FT4 , ECX , XETR:ECX